BR112013014914B8 - composto, composição farmacêutica e uso de um composto - Google Patents

composto, composição farmacêutica e uso de um composto

Info

Publication number
BR112013014914B8
BR112013014914B8 BR112013014914A BR112013014914A BR112013014914B8 BR 112013014914 B8 BR112013014914 B8 BR 112013014914B8 BR 112013014914 A BR112013014914 A BR 112013014914A BR 112013014914 A BR112013014914 A BR 112013014914A BR 112013014914 B8 BR112013014914 B8 BR 112013014914B8
Authority
BR
Brazil
Prior art keywords
compound
formula
compounds
pharmaceutical composition
double bond
Prior art date
Application number
BR112013014914A
Other languages
English (en)
Other versions
BR112013014914B1 (pt
BR112013014914A2 (pt
Inventor
G Olivero Alan
Wei Bin-Qing
Ndubaku Chudi
Elgin Jones Graham
Dotson Jennafer
Wang Lan
Salphati Laurent
James Mclean Neville
Andrew Heald Robert
Lerche Krintel Sussie
Heffron Timothy
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45478511&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013014914(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of BR112013014914A2 publication Critical patent/BR112013014914A2/pt
Publication of BR112013014914B1 publication Critical patent/BR112013014914B1/pt
Publication of BR112013014914B8 publication Critical patent/BR112013014914B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

composto, composição farmacêutica, método de tratar câncer em um paciente e uso são descritos compostos de fórmula i inibidores de pi3k tricíclicos, com atividade anticâncer, atividade anti-inflamatória ou propriedades imunorreguladoras, e mais especificamente com atividade de modulação ou inibitória de pi3 quinase. são descritos métodos para usar os compostos de fórmula i inibidores de pi3k tricíclicos para diagnóstico ou tratamento in vitro, in situ e in vivo, de células de mamíferos, organismos ou condições patológicas associadas. compostos de fórmula i incluem estereoisômeros, isômeros geométricos, tautômeros e sais farmaceuticamente aceitáveis dos mesmos. as linhas tracejadas indicam uma ligação dupla opcional, e pelo menos um alinha tracejada é uma dupla ligação. os substituintes são conforme descritos.
BR112013014914A 2010-12-16 2011-12-15 composto, composição farmacêutica e uso de um composto BR112013014914B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42369410P 2010-12-16 2010-12-16
US61/423,694 2010-12-16
PCT/US2011/065101 WO2012082997A1 (en) 2010-12-16 2011-12-15 Tricyclic pi3k inhibitor compounds and methods of use

Publications (3)

Publication Number Publication Date
BR112013014914A2 BR112013014914A2 (pt) 2016-11-22
BR112013014914B1 BR112013014914B1 (pt) 2020-07-14
BR112013014914B8 true BR112013014914B8 (pt) 2020-08-04

Family

ID=45478511

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013014914A BR112013014914B8 (pt) 2010-12-16 2011-12-15 composto, composição farmacêutica e uso de um composto

Country Status (32)

Country Link
US (5) US8883799B2 (pt)
EP (3) EP2651951B1 (pt)
JP (1) JP5775171B2 (pt)
KR (2) KR20140099556A (pt)
CN (2) CN105859735B (pt)
AR (2) AR084312A1 (pt)
AU (1) AU2011343712B2 (pt)
BR (1) BR112013014914B8 (pt)
CA (1) CA2820078C (pt)
CL (1) CL2013001093A1 (pt)
CO (1) CO6710942A2 (pt)
CR (1) CR20130247A (pt)
DK (1) DK2651951T3 (pt)
EA (1) EA026134B1 (pt)
EC (1) ECSP13012692A (pt)
ES (1) ES2530545T3 (pt)
HK (1) HK1185871A1 (pt)
HR (1) HRP20150127T1 (pt)
IL (1) IL225778A (pt)
MX (1) MX2013006858A (pt)
MY (1) MY164910A (pt)
NZ (1) NZ609448A (pt)
PE (1) PE20140314A1 (pt)
PL (1) PL2651951T3 (pt)
PT (1) PT2651951E (pt)
RS (1) RS53768B1 (pt)
SG (2) SG10201510347QA (pt)
SI (1) SI2651951T1 (pt)
TW (2) TW201500358A (pt)
UA (1) UA109688C2 (pt)
WO (1) WO2012082997A1 (pt)
ZA (1) ZA201304128B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014033196A1 (en) * 2012-08-30 2014-03-06 F. Hoffmann-La Roche Ag Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use
NZ707366A (en) 2012-11-07 2018-11-30 Karus Therapeutics Ltd Novel histone deacetylase inhibitors and their use in therapy
AR095443A1 (es) * 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
AU2014264370B2 (en) 2013-05-10 2017-12-14 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
WO2014185367A1 (ja) * 2013-05-13 2014-11-20 第一三共株式会社 モルホリノプリン誘導体の製造方法
CN104557955B (zh) * 2013-10-23 2017-05-03 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
CN106029663B (zh) * 2013-12-24 2018-06-01 百时美施贵宝公司 作为抗癌剂的新颖三环化合物
CN106659765B (zh) 2014-04-04 2021-08-13 德玛医药 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
KR20230113416A (ko) * 2014-12-18 2023-07-28 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체조절제 및 이의 용도
JP6038111B2 (ja) * 2014-12-27 2016-12-07 ヤマサ醤油株式会社 多置換７−デアザプリン誘導体合成のための２，６−ジクロロ−８−ヨード−７−デアザプリン
KR102623321B1 (ko) * 2015-02-11 2024-01-09 선오비온 파마슈티컬스 인코포레이티드 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체
EP3268373B1 (en) 2015-03-09 2022-04-27 F. Hoffmann-La Roche AG Tricyclic dlk inhibitors and uses thereof
PL3277682T3 (pl) 2015-03-30 2019-09-30 Daiichi Sankyo Company, Limited Pochodne 6-morfolinylo-2-pirazolylo-9h-puryny i ich zastosowanie jako inhibitory pi3k
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
GB201514751D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
WO2017090058A1 (en) * 2015-11-23 2017-06-01 Council Of Scientific & Industrial Research Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof
ES2907574T3 (es) 2015-12-16 2022-04-25 Genentech Inc Proceso para la preparación de compuestos inhibidores de pi3k triciclicos y métodos para su utilización para el tratamiento del cáncer.
ES2788348T3 (es) * 2016-05-24 2020-10-21 Merck Patent Gmbh Derivados heterocíclicos tricíclicos
JP2019520379A (ja) 2016-07-01 2019-07-18 ジー１ セラピューティクス， インコーポレイテッド ピリミジン系の抗増殖剤
CN106008528A (zh) * 2016-07-28 2016-10-12 安徽赛迪生物科技有限公司 一种合成4-氯-5,7-二氢-6h-吡咯并[2,3-d]嘧啶-6-酮的方法
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
CN116514761A (zh) 2016-07-29 2023-08-01 赛诺维信制药公司 化合物、组合物及其用途
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3521290A4 (en) * 2016-09-29 2020-04-22 Daiichi Sankyo Company, Limited CRYSTALS OF [2- (1-METHYL-1H-PYRAZOL-4-YL) -6- (MORPHOLIN-4-YL) -9H-PURIN-8-YL] [4- (MORPHOLIN-4-YL) PIPERIDIN-1 -YL] METHANONE AND PHARMACEUTICAL SAFE SALT THEREOF
CN110300590A (zh) * 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
US11208442B2 (en) 2016-12-02 2021-12-28 Daiichi Sankyo Company, Limited Endo-beta-N-acetylglucosaminidase
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
AU2019335968B2 (en) 2018-09-07 2024-03-07 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compound
ES2958917T3 (es) 2018-10-02 2024-02-16 Syngenta Participations Ag Compuestos de benceno-amida y azina-amida con actividad plaguicida
CN109134480A (zh) * 2018-10-19 2019-01-04 辽宁大学 一种新型4-苯氨基苯并呋喃并[2,3-d]嘧啶类化合物及其应用
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
TW202102489A (zh) 2019-03-29 2021-01-16 瑞士商先正達農作物保護公司 殺有害生物活性之二𠯤-醯胺化合物
KR20210149113A (ko) 2019-04-05 2021-12-08 신젠타 크롭 프로텍션 아게 살충 활성 디아진-아미드 화합물
CA3131861A1 (en) 2019-04-11 2020-10-15 Jurgen Harry Schaetzer Pesticidally active diazine-amide compounds
US20220289715A1 (en) 2019-08-23 2022-09-15 Syngenta Crop Protection Ag Pesticidally active pyrazine-amide compounds
GB201913921D0 (en) * 2019-09-26 2019-11-13 Sentinel Oncology Ltd Pharmaceutical compounds
CN113004303A (zh) * 2019-12-18 2021-06-22 江苏恒瑞医药股份有限公司 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用
WO2021236650A1 (en) 2020-05-19 2021-11-25 G1 Therapeutics, Inc. Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
BR112023025644A2 (pt) 2021-06-09 2024-02-27 Syngenta Crop Protection Ag Compostos de diazina-amida pesticidamente ativos
WO2023072849A1 (en) 2021-10-27 2023-05-04 Syngenta Crop Protection Ag Pesticidally active pyridazinone compounds
WO2023104714A1 (en) 2021-12-10 2023-06-15 Syngenta Crop Protection Ag Pesticidally active pyridazinone compounds
KR20230115493A (ko) 2022-01-27 2023-08-03 인제대학교 산학협력단 특이적 PI3K p110δ 억제제를 유효성분으로 함유하는 스타스민1 관련 질환 예방 또는 치료용 조성물
CN115413669B (zh) * 2022-06-14 2024-03-15 湖南大学 激酶抑制剂及其组合剂在提高植物青枯病抗性中的应用
CN115403593B (zh) * 2022-09-22 2024-02-02 河南师范大学 一种环加成合成手性嘌呤[3,2-c]并噁唑化合物的方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016378A (en) 1959-07-01 1962-01-09 Thomae Gmbh Dr K Amino-substituted purine derivatives
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS4872196U (pt) 1971-12-11 1973-09-10
JPS4872196A (pt) * 1971-12-27 1973-09-29
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
JPS60260579A (ja) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
JPS6216477A (ja) 1985-07-15 1987-01-24 Maruishi Seiyaku Kk 抗ウイルス活性を有する２−（４−ピリジルアミノメチル）−ベンズイミダゾ−ル誘導体
US4740230A (en) 1985-09-13 1988-04-26 Idemitsu Kosan Company Limited Triazine derivatives, and herbicides containing the derivatives as the effective component
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
CA1279648C (en) 1986-07-11 1991-01-29 Haruo Kuriyama 2-(4-pyridylaminometyl)-benzimidazole derivatives having antiviral activity
US4932998A (en) 1986-09-30 1990-06-12 Idemitsu Kosan Company Limited Triazine derivatives, and herbicides comprising the same as the effective ingredient
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
JP3093112B2 (ja) 1994-09-01 2000-10-03 新日本製鐵株式会社 塗覆装鋼製打ち込み部材
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2001083456A1 (fr) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'heteroaryle condenses
WO2003006151A1 (en) 2001-07-12 2003-01-23 Avecia Limited Microencapsulated catalyst, methods of preparation and methods of use thereof
AU2002323475B2 (en) 2001-09-13 2006-09-28 Synta Pharmaceuticals Corp 2-aroylimidazole compounds for treating cancer
CA2463563A1 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US6949644B2 (en) 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
CA2502356A1 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
CA2527079A1 (en) 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
CN1894222A (zh) 2003-08-05 2007-01-10 沃泰克斯药物股份有限公司 作为电压门控离子通道抑制剂的稠合嘧啶化合物
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
KR20060070572A (ko) 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
JP4800216B2 (ja) 2003-10-24 2011-10-26 エグゼリクシス， インコーポレイテッド ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法
WO2005069865A2 (en) 2004-01-13 2005-08-04 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
JP2008508357A (ja) 2004-08-02 2008-03-21 スミスクライン ビーチャム コーポレーション 化学的化合物
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US20080269239A1 (en) 2004-11-11 2008-10-30 Argenta Discovery Ltd. Pyrimidine Compounds as Histamine Modulators
EA019983B1 (ru) 2005-10-07 2014-07-30 Экселиксис, Инк. Ингибиторы mek и способы их применения
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
CL2007001167A1 (es) 2006-04-26 2008-01-25 Genentech Inc Compuestos derivados de pirimidina condensada, inhibidores de p13-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicionfarmaceutica.
BRPI0710866A2 (pt) 2006-04-26 2012-08-14 Hoffmann La Roche compostos farmacÊuticos
CL2007001165A1 (es) 2006-04-26 2008-01-25 Hoffmann La Roche 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares.
US7846929B2 (en) * 2006-04-26 2010-12-07 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
ES2648388T3 (es) 2006-08-23 2018-01-02 Kudos Pharmaceuticals Limited Derivados de 2-metilmorfolin pirido-, pirazo- y pirimido-pirimidina como inhibidores de mTOR
WO2008032162A1 (en) 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
CL2007002866A1 (es) 2006-10-04 2008-07-04 Pharmacopeia Inc Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
JP5443988B2 (ja) 2006-10-16 2014-03-19 メディシス・ファーマシューティカル・コーポレーション 治療用のピラゾリルチエノピリジン
KR101507182B1 (ko) 2006-12-07 2015-03-30 제넨테크, 인크. 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
KR101460816B1 (ko) 2006-12-07 2014-11-12 에프. 호프만-라 로슈 아게 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
US20100130516A1 (en) 2007-03-28 2010-05-27 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
BRPI0810641A2 (pt) 2007-04-12 2019-09-24 Hoffmann La Roche "compostos farmacêuticos".
WO2008152394A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
WO2008152387A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Quinazoline derivatives as pi3 kinase inhibitors
WO2008152390A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
KR20100033484A (ko) * 2007-06-26 2010-03-30 사노피-아벤티스 어닐링된 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 금속 촉매된 합성
WO2009034386A1 (en) 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
ES2399774T3 (es) 2007-09-24 2013-04-03 Genentech, Inc. Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
WO2009045174A1 (en) 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
GB0721095D0 (en) 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
EP2215090B1 (en) 2007-10-26 2015-03-04 F. Hoffmann-La Roche AG Purine derivatives useful as pi3 kinase inhibitors
GB0725218D0 (en) 2007-12-24 2008-02-06 Syngenta Ltd Chemical compounds
EP2252616B1 (en) 2008-01-30 2014-07-23 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
AU2009251291B2 (en) 2008-05-30 2013-05-02 F. Hoffmann-La Roche Ag Purine PI3K inhibitor compounds and methods of use
JP5607614B2 (ja) 2008-06-20 2014-10-15 アストラゼネカ アクチボラグ 組成物及び方法−３５６
KR20110046514A (ko) 2008-07-31 2011-05-04 제넨테크, 인크. 피리미딘 화합물, 조성물 및 사용 방법
JP2012503658A (ja) 2008-09-26 2012-02-09 メルク・シャープ・エンド・ドーム・コーポレイション オキサゾロベンゾイミダゾール誘導体
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
CA2744154A1 (en) 2008-11-20 2010-05-27 Genentech, Inc. Pyrazolopyridine pi3k inhibitor compounds and methods of use
US8158625B2 (en) 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
CA2761445A1 (en) 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US20100331305A1 (en) 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
PL2467387T3 (pl) * 2009-08-20 2015-08-31 Karus Therapeutics Ltd Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu
CN102020657A (zh) * 2009-09-11 2011-04-20 上海艾力斯医药科技有限公司 稠合杂芳基衍生物、制备方法及其应用
US8569296B2 (en) 2009-09-29 2013-10-29 Xcovery Holding Company, Llc PI3K (delta) selective inhibitors
CA2786294A1 (en) 2010-02-22 2011-08-25 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US8293736B2 (en) 2010-07-14 2012-10-23 F. Hoffmann La Roche Ag Purine compounds selective for PI3K P110 delta, and methods of use
JP5766820B2 (ja) 2011-02-09 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｉ３キナーゼ阻害剤としての複素環化合物
CN103582479A (zh) 2011-06-03 2014-02-12 霍夫曼-拉罗奇有限公司 用pi3k抑制剂化合物治疗间皮瘤的方法

Also Published As

Publication number Publication date
CN105859735B (zh) 2018-03-09
SG190890A1 (en) 2013-07-31
ZA201304128B (en) 2014-02-26
PL2651951T3 (pl) 2015-04-30
TWI441824B (zh) 2014-06-21
AR084312A1 (es) 2013-05-08
CN105859735A (zh) 2016-08-17
HRP20150127T1 (en) 2015-03-13
KR20140099556A (ko) 2014-08-12
CL2013001093A1 (es) 2013-09-27
KR101548439B1 (ko) 2015-08-28
IL225778A0 (en) 2013-06-27
US20170233407A1 (en) 2017-08-17
UA109688C2 (xx) 2015-09-25
TW201500358A (zh) 2015-01-01
JP5775171B2 (ja) 2015-09-09
US20220348593A1 (en) 2022-11-03
DK2651951T3 (en) 2014-12-08
BR112013014914B1 (pt) 2020-07-14
IL225778A (en) 2016-10-31
AU2011343712A1 (en) 2013-05-02
PT2651951E (pt) 2015-01-14
ES2530545T3 (es) 2015-03-03
CN103313989B (zh) 2016-05-04
AU2011343712B2 (en) 2015-09-17
TW201302752A (zh) 2013-01-16
EP2813506A1 (en) 2014-12-17
EA201390879A1 (ru) 2013-09-30
KR20130105707A (ko) 2013-09-25
CA2820078C (en) 2019-02-12
RS53768B1 (en) 2015-06-30
US20150079081A1 (en) 2015-03-19
EP2651951B1 (en) 2014-11-19
EA026134B1 (ru) 2017-03-31
JP2014503535A (ja) 2014-02-13
MX2013006858A (es) 2013-07-29
SI2651951T1 (sl) 2015-01-30
US9546182B2 (en) 2017-01-17
US20120171199A1 (en) 2012-07-05
EP3053925A1 (en) 2016-08-10
EP2813506B1 (en) 2016-05-25
PE20140314A1 (es) 2014-03-22
CO6710942A2 (es) 2013-07-15
CA2820078A1 (en) 2012-06-21
CR20130247A (es) 2013-06-28
MY164910A (en) 2018-02-15
CN103313989A (zh) 2013-09-18
EP2651951A1 (en) 2013-10-23
SG10201510347QA (en) 2016-01-28
BR112013014914A2 (pt) 2016-11-22
WO2012082997A1 (en) 2012-06-21
AR122019A2 (es) 2022-08-03
HK1185871A1 (zh) 2014-02-28
US8883799B2 (en) 2014-11-11
NZ609448A (en) 2015-07-31
US20190330235A1 (en) 2019-10-31
ECSP13012692A (es) 2013-08-30

Similar Documents

Publication Publication Date Title
BR112013014914B8 (pt) composto, composição farmacêutica e uso de um composto
BR112013024122A2 (pt) compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso
BR112013020329A2 (pt) compostos heterocíclicos como inibidores da pi3-quinase
EA201490859A1 (ru) Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона
TR201909849T4 (tr) Btk etkinliği inhibitörleri olarak heteroaril piridon ve aza-piridon bileşikleri.
MX2014014828A (es) Compuestos de 5-azaindazol y metodos de uso.
EA201290957A1 (ru) Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения
BR112014032809A8 (pt) urolitinas, usos de uma quantidade eficaz de uma urolitina ou um sal farmaceuticamente aceitável da mesma e composição compreendendo as mesmas
EA201590624A1 (ru) Циклические эфиры пиразол-4-ил-гетероциклил-карбоксамидных соединений и способы их применения
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
CL2011000306A1 (es) Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion.
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
BR112012019635A2 (pt) compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
MY160349A (en) Pyridone and aza-pyridone compounds and methods of use
MX2010002543A (es) Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
MX2011012520A (es) Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
MX2014005285A (es) Compuestos biciclicos de piperazina.
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
NO20084928L (no) Farmasoytiske sammensetninger
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
MX2014005282A (es) Compuestos de 8-fluoroftalazin-1 (2h) -ona.
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
BR112014008495B8 (pt) Composto inibidor da proteína quinase, composição farmacêutica compreendendo-o e uso do mesmo para a fabricação de um medicamento para o tratamento de câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: GENENTECH, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/12/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2584 DE 14/07/2020 QUANTO A FOLHA EXCEDENTE NA MONTAGEM.